Frazier Life Sciences Management, L.P. Erasca, Inc. Call Options Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ERAS
# of Institutions
162Shares Held
222MCall Options Held
20.6KPut Options Held
5.7K-
T. Rowe Price Investment Management, Inc. Baltimore, MD17.3MShares$24.4 Million0.02% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$22.9 Million5.36% of portfolio
-
Logos Global Management LP San Francisco, CA13MShares$18.3 Million3.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.7MShares$17.9 Million0.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY12.3MShares$17.4 Million0.74% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $172M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...